...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis.
【24h】

Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis.

机译:小鼠分枝杆菌增长的发展抑制试验来评估疫苗结核分枝杆菌。

获取原文
获取原文并翻译 | 示例
           

摘要

The development and characterization of new tuberculosis (TB) vaccines has been impeded by the lack of reproducible and reliable in vitro assays for measuring vaccine activity. In this study, we developed a murine in vitro mycobacterial growth inhibition assay for evaluating TB vaccines that directly assesses the capacity of immune splenocytes to control the growth of Mycobacterium tuberculosis within infected macrophages. Using this in vitro assay, protective immune responses induced by immunization with five different types of TB vaccine preparations (Mycobacterium bovis BCG, an attenuated M. tuberculosis mutant strain, a DNA vaccine, a modified vaccinia virus strain Ankara [MVA] construct expressing four TB antigens, and a TB fusion protein formulated in adjuvant) can be detected. Importantly, the levels of vaccine-induced mycobacterial growth-inhibitory responses seen in vitro after 1 week of coculture correlated with the protective immune responses detected in vivo at 28 days postchallenge in a mouse model of pulmonary tuberculosis. In addition, similar patterns of cytokine expression were evoked at day 7 of the in vitro culture by immune splenocytes taken from animals immunized with the different TB vaccines. Among the consistently upregulated cytokines detected in the immune cocultures are gamma interferon, growth differentiation factor 15, interleukin-21 (IL-21), IL-27, and tumor necrosis factor alpha. Overall, we have developed an in vitro functional assay that may be useful for screening and comparing new TB vaccine preparations, investigating vaccine-induced protective mechanisms, and assessing manufacturing issues, including product potency and stability.
机译:和表征的新发展结核病疫苗问题一直困扰着缺乏可再生的和可靠的体外分析测量疫苗活动。研究中,我们开发了一种小鼠体外分枝杆菌生长抑制试验评估直接评估的结核病疫苗免疫脾细胞控制的能力内的结核分枝杆菌的生长被感染的巨噬细胞。保护性免疫反应引起的免疫与五种不同类型的结核病疫苗制剂(牛结核分枝杆菌卡介苗减毒结核分枝杆菌突变株,DNA疫苗,修改后的牛痘病毒株安卡拉(MVA)构建表达四个结核抗原,辅助制定结核病融合蛋白)被检测出来。诱发的分枝杆菌growth-inhibitory反应体外coculture 1周后相关的保护性免疫反应在28天postchallenge体内检测到肺结核的小鼠模型。此外,类似的细胞因子的表达模式在第七天诱发体外培养的吗免疫脾细胞取自动物免疫与不同的结核病疫苗。调节细胞因子检测到免疫coculturesγ干扰素,生长分化因子interleukin-21(IL-27 IL-21)和肿瘤坏死因子α。总的来说,我们已经开发出一种体外功能对于筛选和分析这可能是有用的比较新的结核病疫苗制剂,调查诱发的保护机制和评估生产问题,包括产品强度和稳定性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号